Abstract
Neurotrophic factors comprise a broad family of secreted proteins that have growth promoting, survival promoting and differentiation inducing activities. Disruption of neurotrophic factor signalling is a characteristic of many central and peripheral nervous system disorders, such as Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and peripheral neuropathy and pain. It follows that treating patients with neurotrophic factors might be beneficial in a range of neurological diseases. However, the promising results seen in animal models of disease have not translated well into clinical trials due to the poor pharmacokinetics associated with the intact proteins, in particular, their short in vivo half-life, low blood brain barrier permeability, limited diffusion, and undesirable effects through multiple receptor interactions. This has been the main motivation for the design of small molecule modulators of the neurotrophic factor pathways. The review gives a brief survey of the various strategies to design mimetics that have been reported in the literature with special emphasis on the tandem repeat peptide agonist approach for BDNF/NT-4/5 and N-cadherin mimetics.
CNS & Neurological Disorders - Drug Targets
Title: Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
Volume: 7 Issue: 1
Author(s): Gareth Williams, Gareth Williams, Francisco Molina-Holgado, Francisco Molina-Holgado, Patrick Doherty and Patrick Doherty
Affiliation:
Abstract: Neurotrophic factors comprise a broad family of secreted proteins that have growth promoting, survival promoting and differentiation inducing activities. Disruption of neurotrophic factor signalling is a characteristic of many central and peripheral nervous system disorders, such as Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and peripheral neuropathy and pain. It follows that treating patients with neurotrophic factors might be beneficial in a range of neurological diseases. However, the promising results seen in animal models of disease have not translated well into clinical trials due to the poor pharmacokinetics associated with the intact proteins, in particular, their short in vivo half-life, low blood brain barrier permeability, limited diffusion, and undesirable effects through multiple receptor interactions. This has been the main motivation for the design of small molecule modulators of the neurotrophic factor pathways. The review gives a brief survey of the various strategies to design mimetics that have been reported in the literature with special emphasis on the tandem repeat peptide agonist approach for BDNF/NT-4/5 and N-cadherin mimetics.
Export Options
About this article
Cite this article as:
Williams Gareth, Williams Gareth, Molina-Holgado Francisco, Molina-Holgado Francisco, Doherty Patrick and Doherty Patrick, Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885200
DOI https://dx.doi.org/10.2174/187152708783885200 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings
Current Molecular Pharmacology Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets The Nearest-Neighbor Effect on Random-Coil NMR Chemical Shifts Demonstrated Using a Low-Complexity Amino-Acid Sequence
Protein & Peptide Letters Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems)
CNS & Neurological Disorders - Drug Targets NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
CNS & Neurological Disorders - Drug Targets Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets